Strides Pharma Science to acquire Endo’s manufacturing facility in US along with basket of ANDAs

By: |
August 06, 2021 11:44 AM

The wholly-owned subsidiaries of Strides Pharma Science have entered into definitive agreements with the subsidiaries of Endo International plc to this effect.

Strides Pharma ScienceElaborating on the strategic rationale for the deal, the company said over the last few years, Strides US business has seen a significant ramp up driven by portfolio expansion and strengthening of front-end presence. (Representational image)

Strides Pharma Science on Friday said it will acquire Endo International plc’s manufacturing facility at Chestnut Ridge, New York along with a basket of abbreviated new drug application (ANDAs) for USD 24 million. The wholly-owned subsidiaries of Strides Pharma Science have entered into definitive agreements with the subsidiaries of Endo International plc to this effect.

Under the terms of the agreement, Strides will pay USD 24 million for the acquisition, the company said in a regulatory filing. “The acquisition we have announced today is a very good strategic fit for the business and will help further accelerate our growth momentum for the US market. With this acquisition we have doubled our US portfolio with a potential to launch 5-6 new products each quarter going forward,” R Ananthanarayanan, Managing Director and CEO Strides Pharma Science said.

Elaborating on the strategic rationale for the deal, the company said over the last few years, Strides US business has seen a significant ramp up driven by portfolio expansion and strengthening of front-end presence. The cumulative addressable market for the acquired portfolio is USD 4.7 billion (IQVIA MAT May 2021), the company said. Strides said the facility at Chestnut Ridge, New York has an annual capacity of 2 billion units across semi- solids, liquids, nasal sprays along with oral solids.

The transaction will be financed by a combination of internal accruals and debt financing. The transaction is expected to close in calendar year 2021, subject to customary closing conditions. “The US is now the largest market for Strides contributing 48 per cent of FY21 consolidated revenue. The proposed acquisition will further bolster Strides US presence through acquisition of a multi-dosage facility in the US and a basket of ANDAs cutting across multiple therapeutic segments,” the company added.

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Over 1 crore informal workers registered on e-Shram portal
2Dish TV seeks to extend AGM, says requires regulatory nod for suggested changes on board
3Amazon expands language support for sellers ahead of festive season; teases Great Indian Festival sale